WeLeader Biomedical Co., Ltd. (TPEX:7713)

Market Cap	3.05B +16.0%
Revenue (ttm)	1.11B +11.9%
Net Income	208.56M +22.5%
EPS	4.52 +10.9%
Shares Out	45.48M
PE Ratio	14.81
Forward PE	n/a
Dividend	4.10 (6.12%)
Ex-Dividend Date	Mar 27, 2026

Volume	1,000
Average Volume	16,600
Open	66.60
Previous Close	67.00
Day's Range	66.60 - 67.50
52-Week Range	55.90 - 83.00
Beta	0.11
RSI	38.82
Earnings Date	May 8, 2026

About WeLeader Biomedical

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT centr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7713

Financial Performance

In 2025, WeLeader Biomedical's revenue was 1.11 billion, an increase of 11.92% compared to the previous year's 991.13 million. Earnings were 208.56 million, an increase of 22.53%.